Irinotecan injection
Products billed under this code include Camptosar, Irinotecan HCl.
Payment limit per 20 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Camptosar, Irinotecan HCl.
Payment limit per 20 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Camptosar | Pfizer Inc | 00009-0082-02 | 15 | $23.535 |
| Camptosar | Pfizer Inc | 00009-0112-05 | 5 | $7.845 |
| Camptosar | Pfizer Inc | 00009-7529-03 | 5 | $7.845 |
| Camptosar | Pfizer Inc | 00009-7529-04 | 2 | $3.138 |
| Camptosar | Pfizer Inc | 00009-7529-05 | 15 | $23.535 |
| Camptosar | Pfizer Inc | 00009-7529-10 | 2 | $3.138 |
| Irinotecan HCl | Hikma Pharmaceuticals USA Inc. | 00143-9701-01 | 5 | $7.845 |
| Irinotecan HCl | Hikma Pharmaceuticals USA Inc. | 00143-9702-01 | 2 | $3.138 |
| Irinotecan HCl | Northstar RxLLC | 16714-0027-01 | 2 | $3.138 |
| Irinotecan HCl | Northstar RxLLC | 16714-0131-01 | 5 | $7.845 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Irinotecan HCl | Sagent Pharmaceuticals | 25021-0230-02 | 2 | $3.138 |
| Irinotecan HCl | Sagent Pharmaceuticals | 25021-0230-05 | 5 | $7.845 |
| Irinotecan HCl | Actavis Pharma, Inc. | 45963-0614-51 | 2 | $3.138 |
| Irinotecan HCl | Actavis Pharma, Inc. | 45963-0614-55 | 5 | $7.845 |
| Irinotecan HCl | Ingenus Pharmaceuticals LLC | 50742-0401-02 | 2 | $3.138 |
| Irinotecan HCl | Ingenus Pharmaceuticals LLC | 50742-0402-05 | 5 | $7.845 |
| Irinotecan HCl | Eugia US LLC | 55150-0352-01 | 2 | $3.138 |
| Irinotecan HCl | Eugia US LLC | 55150-0353-01 | 5 | $7.845 |
| Irinotecan HCl | Eugia US LLC | 55150-0354-01 | 15 | $23.535 |
| Irinotecan HCl | Apotex Corp | 60505-6128-00 | 2 | $3.138 |
| Irinotecan HCl | Apotex Corp | 60505-6128-01 | 5 | $7.845 |
| Irinotecan HCl | Apotex Corp | 60505-6272-01 | 5 | $7.845 |
| Irinotecan HCl | Pfizer Inc | 61703-0349-09 | 5 | $7.845 |
| Irinotecan HCl | Pfizer Inc | 61703-0349-16 | 2 | $3.138 |
| Irinotecan HCl | Pfizer Inc | 61703-0349-36 | 25 | $39.225 |
| Irinotecan HCl | FreseniUS Kabi USA, LLC | 63323-0193-52 | 2 | $3.138 |
| Irinotecan HCl | FreseniUS Kabi USA, LLC | 63323-0193-55 | 5 | $7.845 |
| Irinotecan HCl | BluePoint Laboratories | 68001-0480-22 | 5 | $7.845 |
| Irinotecan HCl | BluePoint Laboratories | 68001-0480-35 | 2 | $3.138 |
| Irinotecan HCl | Xiromed, LLC | 70700-0169-22 | 2 | $3.138 |
| Irinotecan HCl | Xiromed, LLC | 70700-0170-22 | 5 | $7.845 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.569 | −$0.282 | 20 MG | Irinotecan injection | v1, posted September 17, 2026 |
| 3Q26 | $1.851 | +$0.319 | 20 MG | Irinotecan injection | v1, posted September 15, 2026 |
| 2Q26 | $1.532 | −$0.262 | 20 MG | Irinotecan injection | v1, posted September 15, 2026 |
| 1Q26 | $1.794 | +$0.043 | 20 MG | Irinotecan injection | v1, posted September 15, 2026 |
| 4Q25 | $1.751 | +$0.354 | 20 MG | Irinotecan injection | v1, posted September 8, 2026 |
| 3Q25 | $1.397 | −$0.243 | 20 MG | Irinotecan injection | v1, posted March 10, 2026 |
| 2Q25 | $1.64 | −$0.334 | 20 MG | Irinotecan injection | v1, posted March 10, 2026 |
| 1Q25 | $1.974 | −$0.524 | 20 MG | Irinotecan injection | v1, posted December 19, 2025 |
| 4Q24 | $2.498 | −$0.214 | 20 MG | Irinotecan injection | v1, posted June 11, 2025 |
| 3Q24 | $2.712 | −$0.796 | 20 MG | Irinotecan injection | v1, posted June 11, 2025 |
| 2Q24 | $3.508 | +$1.563 | 20 MG | Irinotecan injection | v1, posted March 11, 2025 |
| 1Q24 | $1.945 | −$0.119 | 20 MG | Irinotecan injection | v1, posted December 19, 2024 |
| 4Q23 | $2.064 | −$0.939 | 20 MG | Irinotecan injection | v1, posted October 10, 2024 |
| 3Q23 | $3.003 | +$0.843 | 20 MG | Irinotecan injection | v1, posted June 5, 2024 |
| 2Q23 | $2.16 | −$0.268 | 20 MG | Irinotecan injection | v1, posted February 23, 2024 |
| 1Q23 | $2.428 | −$0.176 | 20 MG | Irinotecan injection | v1, posted December 6, 2023 |
| 4Q22 | $2.604 | +$0.231 | 20 MG | Irinotecan injection | v1, posted June 22, 2023 |
| 3Q22 | $2.373 | +$0.076 | 20 MG | Irinotecan injection | v1, posted June 9, 2023 |
| 2Q22 | $2.297 | −$0.152 | 20 MG | Irinotecan injection | v1, posted December 14, 2022 |
| 1Q22 | $2.449 | +$0.101 | 20 MG | Irinotecan injection | v1, posted June 8, 2022 |
| 4Q21 | $2.348 | −$0.145 | 20 MG | Irinotecan injection | v1, posted June 2, 2022 |
| 3Q21 | $2.493 | +$0.066 | 20 MG | Irinotecan injection | v1, posted June 2, 2022 |
| 2Q21 | $2.427 | −$0.022 | 20 MG | Irinotecan injection | v1, posted March 1, 2022 |
| 1Q21 | $2.449 | – | 20 MG | Irinotecan injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.